Beta Bionics (NASDAQ:BBNX) Now Covered by Analysts at Jefferies Financial Group

Jefferies Financial Group began coverage on shares of Beta Bionics (NASDAQ:BBNX) in a research note released on Monday morning, MarketBeat.com reports. The brokerage issued a buy rating and a $30.00 price objective on the stock.

Other research analysts also recently issued research reports about the stock. Truist Financial raised their target price on shares of Beta Bionics from $23.00 to $28.00 and gave the company a “buy” rating in a research report on Thursday, September 24th. Wells Fargo & Company started coverage on shares of Beta Bionics in a research report on Wednesday, September 23rd. They issued an “overweight” rating and a $28.00 price target for the company. Robert W. Baird increased their price objective on shares of Beta Bionics from $14.00 to $16.00 and gave the company a “neutral” rating in a research note on Tuesday, September 15th. Weiss Ratings raised shares of Beta Bionics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, August 18th. Finally, Leerink Partners boosted their price objective on shares of Beta Bionics from $24.00 to $27.00 and gave the stock an “outperform” rating in a research note on Monday, September 14th. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $24.00.

Beta Bionics Trading Up 1.3%

Shares of Beta Bionics stock opened at $17.86 on Monday. The firm has a market cap of $803.52 million, a P/E ratio of -10.82 and a beta of 3.39. Beta Bionics has a 12 month low of $8.80 and a 12 month high of $32.71. The stock’s fifty day moving average price is $18.85 and its 200-day moving average price is $15.06.

Beta Bionics (NASDAQ:BBNX) last released its quarterly earnings data on Wednesday, July 29th. The company reported ($0.53) earnings per share for the quarter, beating the consensus estimate of ($0.62) by $0.09. Beta Bionics had a negative return on equity of 26.30% and a negative net margin of 61.31%. The firm had revenue of $32.01 million during the quarter. Analysts forecast that Beta Bionics will post -2.02 earnings per share for the current year.

Insider Buying and Selling at Beta Bionics

In other news, insider Mark Hopman sold 30,779 shares of the firm’s stock in a transaction dated Wednesday, September 16th. The shares were sold at an average price of $20.13, for a total value of $619,581.27. Following the sale, the insider directly owned 56,479 shares in the company, valued at approximately $1,136,922.27. This trade represents a 35.27% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Steven Russell sold 4,221 shares of the firm’s stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $19.11, for a total transaction of $80,663.31. Following the completion of the sale, the insider owned 169,628 shares in the company, valued at $3,241,591.08. This represents a 2.43% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders sold 97,697 shares of company stock valued at $1,907,034. 5.30% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Beta Bionics

Several institutional investors have recently bought and sold shares of the company. BlackRock Inc. acquired a new position in shares of Beta Bionics during the second quarter worth $52,340,000. Eversept Partners LP purchased a new stake in shares of Beta Bionics during the 4th quarter valued at $20,667,000. 12 West Capital Management LP purchased a new stake in shares of Beta Bionics during the 4th quarter valued at $17,520,000. Bank of America Corp DE acquired a new stake in shares of Beta Bionics in the 2nd quarter worth $8,566,000. Finally, Perceptive Advisors LLC boosted its position in shares of Beta Bionics by 39.8% in the 1st quarter. Perceptive Advisors LLC now owns 842,944 shares of the company’s stock worth $8,446,000 after purchasing an additional 240,000 shares in the last quarter.

Trending Headlines about Beta Bionics

Here are the key news stories impacting Beta Bionics this week:

• Positive Sentiment: A trading report noted that BBNX shares increased approximately 3.8%, suggesting some short-term buying interest. However, the report did not identify a new fundamental catalyst or change to the company’s outlook. Beta Bionics Shares Up 3.8% – Still a Buy?
• Neutral Sentiment: Several law firms reminded investors that November 3, 2026 is the deadline to seek appointment as lead plaintiff in a proposed securities class action covering purchases made from July 30, 2025, through February 24, 2026. These notices are directed at investors who may have suffered losses and do not establish that Beta Bionics is liable. Rosen securities class action deadline notice
• Negative Sentiment: The proposed securities-fraud litigation alleges that investors were harmed by disclosures concerning FDA compliance and alleged FDA concerns involving Beta Bionics’ automated insulin-delivery system, the iLet. The notices state that related revelations previously caused sharp declines in the stock. The litigation creates potential legal costs, reputational risk and an overhang for BBNX until the allegations and regulatory issues are clarified. Beta Bionics securities fraud class action and iLet FDA compliance

Beta Bionics Company Profile

Beta Bionics, Inc is a medical technology company focused on developing and commercializing automated insulin delivery systems for people with insulin-requiring diabetes. Its lead product is the iLet Bionic Pancreas, an insulin pump system designed to automate much of the insulin-dosing process and reduce the daily burden associated with diabetes management.

The iLet Bionic Pancreas uses continuous glucose monitoring data and the company’s dosing algorithms to deliver insulin. Unlike conventional insulin pumps that generally require users to calculate meal doses, the system is designed to simplify mealtime dosing by using a person’s body weight and meal announcements as key inputs.